MEF2C and Alzheimer disease: Conversely, in AD-MSCs treated with 5-Azacytidine alone and with growth factors, MEF2c expression increased by 6.3-fold and 6.9-fold, respectively, compared with the control AD-MSCs, with no significant change between the two treated groups (p = 0.99).